Out-licensing
- Out-licensing
- View
Naltrexone 50 mg film tablet:
Mechanism of action
Full description
Naltrexone is a Mu-, Kappa and Delta-Receptor Antagonist. It has a stronger affinity to the opioid receptors than any opioid. It is indicated as adjunctive therapy in the maintenance of formerly opioid dependent patients who have ceased the use of opioids such as e.g. Heroin or Morphine. Naltrexone is also indicated in the treatment of alcohol dependence, as a component of a comprehensive psychotherapeutic or psychological alcoholism counselling program to support abstinence and reduce the risk of relapse. Target groups are Drug Treatment Centres, psychiatrists and physicians treating former opioid- or alcohol addicts.
Development status
Patent information
Off patent
Type of business relationship sought
Country-specific or regional distribution contract
Related reports
Licensing contact
Company details
OrPha Swiss is looking of in - and out-licensing opportunities in the field of anaesthesia, intensive care, neurology, pulmonary hypertension and addiction medicine
View profileRelated technologies
- Novel Benztropine Analogs for Treatment of Cocaine Abuse and Other Mental Disorders
- Potent Pharmacophoric Delta- and Mu-Opioid Receptor Antagonists and Conversion of Endomorphin Mu-Opioid Agonists to Antagonists
- A new, non-abusable opioid medication for the indication opioid substitution
- Benztropinamine Analogs as Dopamine Transport Inhibitors
- Product enhancement of small and large molecules in a range of dosage forms
Related categories
- Industry sector
- Pharmaceutical / Generics
- Pharmaceutical
- Pharmaceutical / Prescription
- Therapeutic target
- Central Nervous System / Psychiatric / Addiction
- Central Nervous System / Psychiatric / Alcoholism
- Central Nervous System
- Central Nervous System / Psychiatric / Cocaine addiction
- Central Nervous System / Psychiatric / Opioid dependency
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us